Trever G. Bivona

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 1212: Spatial transcriptomics reveals distinct SPP1-CD44 signaling networks in neoadjuvant osimertinib treated EGFR mutant non-small cell lung cancer.

  Cancer Research · 2026-04-03

• Abstract 7030: Tumor-macrophage crosstalk promotes resistance to EGFR targeted therapy in lung adenocarcinoma.

  Cancer Research · 2026-04-03

• Abstract 5335: Integrated machine learning and large language models reveal molecular determinants of survival and treatment response in KRAS-mutant lung cancer.

  Cancer Research · 2026-04-03

• FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy

  Cancer Research · 2026-03-10 · 1 citations

• Challenges and advances in drug resistance and tolerance in cancer

  Journal of Experimental & Clinical Cancer Research · 2026-03-04

• Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML

  Scientific Data · 2026-02-11

• Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies

  Nature Communications · 2026-02-07 · 1 citations

• Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in <i>BRAF</i> -Altered Solid Tumors or <i>NRAS</i> -Mutant Melanoma

  JCO oncology advances. · 2026-01-01 · 1 citations

• Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap

  Nature Chemical Biology · 2025-11-18 · 7 citations

• Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesPreprint

  Research Square · 2025-10-09

• P3.03.02 WEE1 as the Target for Circumvention of ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutated Lung Cancer

  Journal of Thoracic Oncology · 2025-10-01

• <i>In vivo</i> manipulation of the protein homeostasis network in rhabdomyosarcoma

  Oncotarget · 2025-08-29 · 3 citations

• Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis

  Journal of Clinical Investigation · 2025-08-28 · 14 citations

• Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticityPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-06 · 1 citations

• Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer

  Journal of Thoracic Oncology · 2025-06-13 · 9 citations

• Acquired resistance in cancer: towards targeted therapeutic strategies

  Nature reviews. Cancer · 2025-06-03 · 78 citations

• Actionable biological programs to enhance EGFR-targeted therapy response unveiled by single-cell lineage tracing in clinically relevant lung cancer modelsPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-05-23

• BRAF ^V600E -Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-05-09

• Immune Mesenchymal Crosstalk Induces ARG1 Dependent Profibrotic Metabolism

  American Journal of Respiratory and Critical Care Medicine · 2025-05-01

• Abstract 5510: Targeting BET, Hippo-YAP and RAS-MAPK signaling interplay in lung cancer and therapy resistance

  Cancer Research · 2025-04-21